Literature DB >> 23791930

Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function.

Tanya Rihtman1, Shula Parush, Asher Ornoy.   

Abstract

This prospective, observational study assessed the development of preschool children aged 3-6 years, 11 months (n=124) after in-utero anti-epileptic drug (AED) monotherapy exposure to valproic acid (VPA) (n=30, mean age 52.00[±15.22] months) and lamotrigine (LT) (n=42, mean age 50.12[±12.77] months), compared to non-exposed control children (n=52, mean age 59.96[±14.51] months). As a combined group, AED-exposed children showed reduced non-verbal IQ scores, and lower scores on motor measures, sensory measures, and parent-report executive function, behavioral and attentional measures. When the VPA- and LT-exposed groups were analyzed separately, no cognitive differences were found, but control-VPA and control-LT differences emerged for most motor and sensory measures as well as control-VPA parent-report behavioral and attentional differences. No differences were noted between the VPA and LT groups. These findings suggest that VPA- and LT-exposed children should be monitored on a wider range of developmental measures than currently used, and at differing developmental stages.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Developmental outcomes; Intra-uterine AED exposure; Lamotrigine; Monotherapy; Valproic acid

Mesh:

Substances:

Year:  2013        PMID: 23791930     DOI: 10.1016/j.reprotox.2013.06.001

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  11 in total

Review 1.  Neurodevelopmental Effects of Antiepileptic Drugs.

Authors:  Marissa Kellogg; Kimford J Meador
Journal:  Neurochem Res       Date:  2017-04-19       Impact factor: 3.996

2.  Epilepsy (generalised seizures).

Authors:  J Helen Cross
Journal:  BMJ Clin Evid       Date:  2015-04-17

Review 3.  [Affective disorders during pregnancy : Therapy with antidepressants and mood stabilizers].

Authors:  N Bergemann; W E Paulus
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

4.  Effects of developmental alcohol and valproic acid exposure on play behavior of ferrets.

Authors:  Thomas E Krahe; Claudio C Filgueiras; Alexandre E Medina
Journal:  Int J Dev Neurosci       Date:  2016-05-18       Impact factor: 2.457

Review 5.  An Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment Outcomes.

Authors:  Elizabeth E Gerard; Kimford J Meador
Journal:  J Pediatr Genet       Date:  2015-06

Review 6.  Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.

Authors:  Rebecca Bromley; Jennifer Weston; Naghme Adab; Janette Greenhalgh; Anna Sanniti; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30

7.  Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.

Authors:  Yfke Huber-Mollema; Frans J Oort; Dick Lindhout; Roos Rodenburg
Journal:  Epilepsia       Date:  2019-06       Impact factor: 5.864

Review 8.  Mood stabilizers in pregnancy and lactation.

Authors:  Sandeep Grover; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2015-07       Impact factor: 1.759

9.  Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France.

Authors:  Joël Coste; Pierre-Olivier Blotiere; Sara Miranda; Yann Mikaeloff; Hugo Peyre; Franck Ramus; Mahmoud Zureik; Alain Weill; Rosemary Dray-Spira
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

10.  Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study.

Authors:  Pierre-Olivier Blotière; Sara Miranda; Alain Weill; Yann Mikaeloff; Hugo Peyre; Franck Ramus; Zureik Mahmoud; Joël Coste; Rosemary Dray-Spira
Journal:  BMJ Open       Date:  2020-06-07       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.